Behind Cuba’s Successful Pandemic Response

Cuba’s long-standing commitment to health has led to a successful COVID-19 pandemic response, but it is threatened by financial and supplier issues.

As The Lancet Infectious Diseases went to press, Cuba was due to launch a phase 3 trial of its subunit conjugate vaccine against COVID-19. Soberana-2 is one of four candidate COVID-19 vaccines in development in Cuba. It is produced by the Finlay Institute in Havana. On the basis of as-yet-unpublished results from early-stage clinical trials, Vicente Verez-Bencomo, director-general of the Finlay Institute, expects the vaccine to show an efficacy in the region of 80–95%. “We are very optimistic”, he said. If everything goes according to plan, Cuba could start a mass vaccination programme for its 11·2 million citizens sometime in the summer.

Continue reading at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00159-6/fulltext
Please join the conversation on Caribbean Empowerment’s Facebook page at https://www.facebook.com/groups/2583126101949661/ Or, you can comment by emailing us at: caribbeanempowerment@pm.me

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s